ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning

被引：0
|
作者：
Bryan J. Schneider
Andrew C. Chang
机构：
[1] University of Michigan,Department of Internal Medicine
[2] University of Michigan,Department of Surgery
来源：
Annals of Surgical Oncology | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This ASO perspective reviews the findings of a randomized placebo-controlled, clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma, reported recently by the Checkmate 577 investigators. The use of postoperative immunotherapy represents a significant paradigm shift for managing patients who have had limited evidence-based treatment options after completing neoadjuvant chemoradiation followed by resection for these aggressive malignancies.
引用
下载
收藏
页码：2735 / 2738
页数：3
相关论文
共 50 条
  • [1] ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning
    Schneider, Bryan J.
    Chang, Andrew C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (05) : 2735 - 2738
  • [2] Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
    Kelly, Ronan J.
    Ajani, Jaffer A.
    Kuzdzal, Jaroslaw
    Zander, Thomas
    Van Cutsem, Eric
    Piessen, Guillaume
    Mendez, Guillermo
    Feliciano, Josephine
    Motoyama, Satoru
    Lievre, Astrid
    Uronis, Hope
    Elimova, Elena
    Grootscholten, Cecile
    Geboes, Karen
    Zafar, Syed
    Snow, Stephanie
    Ko, Andrew H.
    Feeney, Kynan
    Schenker, Michael
    Kocon, Piotr
    Zhang, Jenny
    Zhu, Lili
    Lei, Ming
    Singh, Prianka
    Kondo, Kaoru
    Cleary, James M.
    Moehler, Markus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1191 - 1203
  • [3] PHARMACOECONOMIC ANALYSIS OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER IN SWITZERLAND
    Oniangue-Ndza, C.
    Strittmatter, G.
    Lucas, A.
    Wilson, M.
    Kassahun, S.
    Singh, P.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [4] Adjuvant nivolumab for resected gastroesophageal cancer
    不详
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (06) : 368 - 368
  • [5] A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
    Casabianca, Paul
    Massetti, Marc
    Cotte, Francois-Emery
    Moreau, Romain
    Kassahun, Sarah
    Singh, Prianka
    Kim, Inkyu
    Gaudin, Anne-Francoise
    Piessen, Guillaume
    Leleu, Henri
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 689 - 699
  • [6] Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer
    Chartier, Julie
    Coutzac, Clelia
    [J]. BULLETIN DU CANCER, 2022, 109 (04) : 389 - 390
  • [7] A COST-EFFECTIVENESS ANALYSIS (CEA) OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN FRANCE
    Paul, C.
    Massettti, M.
    Cotte, F. E.
    Moreau, R.
    Kassahun, S.
    Singh, P.
    Kim, I
    Gaudin, A. F.
    Leleu, H.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S180 - S180
  • [8] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN CANADA
    Amadi, A.
    Toor, K.
    Keeney, E.
    Thom, H.
    Singh, P.
    Kim, I
    Mameri, E.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
  • [9] FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease
    Horiba, M. Naomi
    Casak, Sandra J.
    Mishra-Kalyani, Pallavi S.
    Roy, Pourab
    Beaver, Julia A.
    Pazdur, Richard
    Kluetz, Paul G.
    Lemery, Steven J.
    Fashoyin-Aje, Lola A.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5244 - 5248
  • [10] Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy: First Results of the CheckMate 577 Study
    Kelly, R. J.
    Ajani, J.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Zhu, L.
    Lei, M.
    Kondo, K.
    Cleary, J. M.
    Moehler, M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S41 - S42
12345